216 related articles for article (PubMed ID: 30386383)
1. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets
Hajalirezay Yazdi S; Paryan M; Mohammadi-Yeganeh S
Cell Mol Biol Lett; 2018; 23():51. PubMed ID: 30386383
[TBL] [Abstract][Full Text] [Related]
2. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
[TBL] [Abstract][Full Text] [Related]
4. Assessment of
Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
[TBL] [Abstract][Full Text] [Related]
6. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
[TBL] [Abstract][Full Text] [Related]
7. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo.
Mohammadi-Yeganeh S; Hosseini V; Paryan M
J Cell Physiol; 2019 Aug; 234(10):18317-18328. PubMed ID: 30945294
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
[TBL] [Abstract][Full Text] [Related]
9. The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.
Fritz HK; Gustafsson A; Ljungberg B; Ceder Y; Axelson H; Dahlbäck B
PLoS One; 2015; 10(8):e0135991. PubMed ID: 26287733
[TBL] [Abstract][Full Text] [Related]
10. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.
Cho CY; Huang JS; Shiah SG; Chung SY; Lay JD; Yang YY; Lai GM; Cheng AL; Chen LT; Chuang SE
RNA; 2016 Feb; 22(2):303-15. PubMed ID: 26667302
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
[TBL] [Abstract][Full Text] [Related]
12. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p.
Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y
EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
[TBL] [Abstract][Full Text] [Related]
16. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
18. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
[TBL] [Abstract][Full Text] [Related]
19. TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer.
Breunig C; Erdem N; Bott A; Greiwe JF; Reinz E; Bernhardt S; Giacomelli C; Wachter A; Kanthelhardt EJ; Beißbarth T; Vetter M; Wiemann S
Mol Oncol; 2018 Sep; 12(9):1447-1463. PubMed ID: 30004628
[TBL] [Abstract][Full Text] [Related]
20. miR-141 as potential suppressor of β-catenin in breast cancer.
Abedi N; Mohammadi-Yeganeh S; Koochaki A; Karami F; Paryan M
Tumour Biol; 2015 Dec; 36(12):9895-901. PubMed ID: 26164002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
